Risk of NSF in Stage 4 or 5 CKD After Group II Gadolinium-Based Contrast Agent Receipt

This systematic review and meta-analysis assess the pooled risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent.

Read the full article here

Related Articles